The Alava consulting team has supported numerous antibody-based programs as well as gene and cell therapies in preclinical and clinical development. This includes experience with AAV and a broad range of viral and nucleic acid based vectors, and cell-based products including MSC-based, iPSC-based, and CAR-T products. Our team has helped virtual and near-virtual startups manage the transition from discovery science to fully capable CMC and regulatory teams supporting clinical testing, often helping maintain lean and outsourced operations while securing funding and building an internal team.
